IVEH - Ives Health Company (fka IVEH)

[jmhollen]

SEC NEWS DIGEST
Issue 2003-21 January 31, 2003
COMMISSION ANNOUNCEMENTS

SECURITIES AND EXCHANGE COMMISSION ANNOUNCES AVAILABILITY OF OPTIONS INTERMARKET LINKAGE

Options Intermarket Linkage Provides for Access Among Markets, Better Ensures
Customer Orders Trade at Best Published Price

The Commission today announced the implementation by the options
exchanges of the intermarket linkage.

Since the expansion of multiple listing of options, and in particular
over the past year, the Commission has encouraged the options exchanges
to develop a linkage to ensure that customers' orders are executed at
the best published price.

Today's implementation of the linkage by the options exchanges is the
culmination of the efforts of the five options exchanges: the American
Stock Exchange, the Chicago Board Options Exchange, the International
Securities Exchange, the Pacific Exchange, and the Philadelphia Stock
Exchange.

"The implementation of this linkage is a credit to the options exchanges
and I commend their hard work in making it a reality." Chairman Harvey
L. Pitt said. "This linkage is a victory for investors who are now
better assured that their orders will be executed at the best published
price."

Today, the linkage is available in 14 option classes to those orders
that are eligible for automatic execution, which are the smaller-sized
orders. The availability of the linkage for these smaller-sized orders
will be rolled out to all classes over the next month. Beginning April
30, the exchanges will roll out the linkage for all other orders. For
more information on the Commission's recent efforts with regard to the
options intermarket linkage, see the SEC News Digest, Issue 2002-238
(December 11, 2002) at http://www.sec.gov/news/digest/12-11.txt. (Press
Rel. 2003-17)

ENFORCEMENT PROCEEDINGS

IN THE MATTER OF IVES HEALTH COMPANY, INC.

An Administrative Law Judge has issued an order entering default in the
Matter of Ives Health Company, Inc. The Order Instituting Proceedings
(OIP) alleged that a U.S. District Court permanently enjoined Ives
Health Company, Inc. from violating Sections 5(a) and 17(a) of the
Securities Act of 1933 and Sections 10(b) and 13(a) of the Securities
Exchange Act of 1934 and Rules 10b-5, 12b-20, 12b-25, 13a-1 and 13a-13
thereunder. The order finds the allegations in the OIP to be true and,
pursuant to Section 12(j) of the Securities Exchange Act of 1934 revokes
the registration of the common stock of Ives Health Company, Inc.
(Rel. 34-47291; File No. 3-10871)

[rainebow]

there's an update on IVEH, and the indictments, today on stockpatrol.com.

[shaolin]

Good finish today. Hope tommorrow does as well. Would be a good time for PR unless it is just a re-hash of the previous one.
LOL shaolin

[jmhollen]

Ives Health Founder Scheduled to Interview on Wisdom Radio, RadioNet and MarketMarquee This Week

Discussions to Surround T-Factor and Company Revenues
BUSINESS WIRE

CLAREMORE, Okla., Feb. 21 — Ives Health Company (OTCBB:IVEH) announced today that the Company's Founder and Chairman of the Board, Keith Ives, will be interviewed by Wisdom Radio, RadioNet and MarketMarquee this week.

Keith Ives stated: "We are beginning to receive more attention from the media as T-Factor(TM) gains momentum. The response from the HIV community has been much greater than we reasonably expected and we believe T-Factor(TM) is the only naturalpath remedy on the market capable of increasing T-Cell counts dramatically. We expect this trend to continue."

The schedule is as follows:

Wed., Feb 21 MarketMarquee (not available live)
Fri., Feb 23 RadioNet Internet Talk Radio (not available live)
Sat., Feb 24 Wisdom Radio 12:00 noon CST


Check your local radio listings for availability in your area (also available through webcasting at http://www.wisdomradio.com).

Wisdom Radio will have a listener call-in segment during the interview in which the public will be able to ask questions of Keith Ives. Members of the public can call 1-800/655-2112 during the interview for more information. RadioNet will accept suggested questions from the public that are submitted prior to the interview. Please e-mail suggestions to [e-mail].

Links to the archived interviews will be provided on the Company's website at http://www.iveshealth.com. The results of the Java Project, the revolutionary study confirming the potency of T-Factor, are also posted on the Company's website. According to many popular sources, over 250 million people are infected by HIV worldwide.

About the Java Project and T-Factor(TM)

The Java Project was a landmark AIDS study carried out by Dr. Slayton-Bedeen, along with the World Health Organization in Jakarta and Bangkok. The project found that new hormonal inhibitors of the Human Immunodeficiency Virus (HIV), like T-Factor(TM), might initiate profound and sustained suppression of HIV replication. The T-Factor(TM) formula was administered to 186 HIV-positive patients of Asian descent with elevated HIV RNA and decreased CD-4 counts, over a period of 24 weeks. The results were dramatic, with over 80% of patients experiencing documented decreases in HIV RNA and enhanced CD-4 counts after 24 weeks.

The T-Factor(TM) formula, acquired by Ives Health Company in 1998, is all-natural, has virtually no side effects, and is readily available over the Internet at http://www.iveshealth.com. T-Factor(TM) currently costs less than $50.00 per month, versus as much as $2,400.00 per month for current HIV drug therapies. According to Ives Health, T-Factor differentiates itself from other HIV drugs under development, like the Gilead Sciences (Nasdaq:GILD) product, because T-Factor is all-natural with virtually no side effects, yet has been proven effective in over 80% of tested patients. T-Factor is currently available on the market.

New studies are ongoing in the United States and recently began in Europe. Findings will be released as the data is reported and validated. T-Factor(TM), not a cure for HIV, is intended to extend the lives of those afflicted with the virus.

About Wisdom Radio

Our family of media outlets -- WISDOM(R) Internet, WISDOM(R) Television and WISDOM(R) Radio -- were created to respond to our country's booming appetite for information about personal growth, alternative medicine, social consciousness, spirituality, relationships and global issues.

Our champion for the WISDOM(R) family is Turner Vision founder/president Bill Turner, an altruistic, optimistic man who strongly believes in the universal laws of nature. Motivated by his own thirst for knowledge about how to better himself, he launched the three Turner Vision affiliates -- the much-lauded WISDOM(R) Television, WISDOM(R) Radio and now WISDOM(R) Internet.

About MarketMarquee

MarketMarquee is an Internet-based business specializing in investor relations. MarketMarquee strives to provide the ultimate service to its clients and members through customer profiles, interviews, and investor relations. Since its inception, MarketMarquee.com has become one of the Internet's premier destinations for corporate interviews. According to a spokesperson from MarketMarquee: "Too many publicly traded companies neglect to communicate their corporate vision with the investment community. MarketMarquee.com gives management of all companies the opportunity to successfully communicate its goals with the general public -- free of cost." All interested parties may direct inquiries to [e-mail].

About RadioNet

Founded in 1994 in Santa Cruz, California, RadioNet was one of the first radio shows to chronicle the digital revolution. Started on the local station KSCO, RadioNet enhanced traditional radio with streaming audio technology to bring the show to a worldwide audience. Exploring topics such as privacy, free speech and how-to's, the RadioNet crew hosts the people who make it happen on the Internet. From Mark Pesce, the creator of VRML, to Esther Dyson, one of the founding members of the Electronic Frontier Foundation, the RadioNet crew explores the how and the why of the Internet.

A Vivo recording of a 1997 television interview with John Bates and Scott Free of RadioNet on The Internet Cafe can be found at: www.cmptv.com/internetcafe/shows/97-98/0142radio/0142a-videos.html.

About Ives Health Company

Ives Health Company is committed to improving
consumers' "total health" through their high-quality natural remedies and homeopathic medicines. Ives product formulations use 98.3% pure natural ingredients and deliver an astounding 90% of the active ingredients into the bloodstream. The Company's products compete in the $99.2 billion diet and nutritional product arena under the following branded names: Pharmacy Health and Diet Program(R), T-Factor(TM) Immune Enhancement System, Vegi Bears(TM) (a nutritional snack) and other natural remedies for aches & pains, acne (a non-topical oral treatment), allergy, antacid, arthritis, cough & sore throat, energy, headache, sinus, PMS relief, prostate relief and cholesterol control, among others. Please visit http://www.iveshealth.com to purchase or to learn more about the Ives family of homeopathic medicines, weight management and natural remedy products.

Copyright 2001 Business Wire

[jmhollen]

Ives Health to Post Summary of the Landmark Java Project That Proves ``T-Factor' Increases T-Cell (CD-4) Cell Count in HIV/AIDS Patients

BUSINESS WIRE

CLAREMORE, Okla., Feb. 19 — Ives Health Company (OTCBB:IVEH):

Public Unveiling of the Java Project Study

Ives Health's ``T-Factor,' an All-Natural Therapy, Increase

Ives Health Company (OTCBB:IVEH) announced today that in order to facilitate the public's unbelievable response to T-Factor(R) and the Java Project, the Company is making a brief summary of the Project, that will include patient profiles, available at http://www.iveshealth.com.

The results of this groundbreaking study are now gaining worldwide attention from both the investment and healthcare communities.

Keith Ives, President and Founder of Ives Health Company, stated: "The sheer amount of excitement surrounding this product has been daunting. When we found the product three years ago, T-Factor(R) was an unsightly paste that had to be administered through a stomach tube. Thanks to years of dedicated research, we have solved the problems of putting the formula in a pill that is easily swallowed, and preserving that formula until it reaches the consumer. This has required both hard work and vision on the part of our team, our investors, and our clients. We could not be more enthusiastic about helping to improve the lives of hundreds of millions of people who are infected with HIV."

T-Factor(R) was released to the public on February 13, 2001, on Ives Health Company's website at http://www.iveshealth.com. Mr. Ives continued: "Because the product has almost no side effects, we are trying to get the word out through HIV and AIDS support groups around the country. We are also attempting to have the product tested and notarized by a celebrity who is battling HIV. HIV is a terrible virus and the enthusiasm that the investment community is showing over T-Factor will help us get the word out to millions of people who desperately need our help."

About the Java Project and T-Factor(R)

The Java Project was a landmark AIDS study carried out by Dr. Slayton-Bedeen, an Immunologist and T-Factor(R) Founder, along with the World Health Organization in Jakarta and Bangkok. The project found that new hormonal inhibitors of the Human Immunodeficiency Virus (HIV), like T-Factor(R), might initiate profound and sustained suppression of HIV replication. The T-Factor(R) formula was administered to 186 HIV-Positive patients of Asian descent with elevated HIV RNA and decreased CD-4 counts, over a period of 24 weeks. The results were dramatic, with over 80% of patients experiencing documented decreases in HIV RNA and enhanced CD-4 counts after 24 weeks.

The T-Factor(R) formula, acquired by Ives Health Company in 1998, is all-natural, has virtually no side effects, and is readily available over the Internet at http://www.iveshealth.com. T-Factor(R) costs less than $3.00 per day versus $80.00 per day for current HIV drug therapies. New studies are on-going in the United States and recently began in Europe. Findings will be released as the data is reported and validated. T-Factor(R) is not a cure for HIV, but is intended to extend the lives of those inflicted with the virus.

About Ives Health Company

Ives Health Company is committed to improving consumers "Total Health" through their high-quality natural remedies and homeopathic medicines. Ives product formulations use 98.3% pure natural ingredients and deliver an astounding 90% of the active ingredients into the bloodstream. The Company's products compete in the $99.2 billion diet and nutritional product arena under the following branded names: Pharmacy Health and Diet Program(R), T-Factor(R) Immune Enhancement System, Vegi Bears(TM) (a nutritional snack) and other natural remedies for Aches & Pains, Acne (a non-topical oral treatment), Allergy, Antacid, Arthritis, Cough & Sore Throat, Energy, Headache, Sinus, PMS relief, Prostate relief, and Cholesterol control, among others. Please visit http://www.iveshealth.com to purchase or to learn more about the Ives family of homeopathic medicines, weight management and natural remedy products.


.

[jmhollen]

10-4.......

[shaolin]

Man oh man, what a day. I haven't seen a stock move like that in one day ever. It will be interesting to see if the price will hold. Seemed like the majority of movement was between 800k and 2 mil. The drops didn't seem to happen on big blocks. I'm not that smart on these things but it seems to me that this one might have a float that is getting pretty small. I have to admit that I didn't DD this one , I just stumbled into it at 137% gain and knew it was gonna roll. I guess tomorrow will tell. Again the big blocks didn't seem to be there like I expected. Maybe the daytraders missed this one, LOL--shaolin

[jmhollen]

http://invest.iveshealth.com/store/productdetail.asp?productid=301

John